RNA Expression Measured In Tissue Sections
|
By LabMedica International staff writers Posted on 12 Jun 2012 |
|
Scientists are able to measure RNA expression directly in a tissue section at single-copy sensitivity.
The QuantiGene ViewRNA ISH tissue assay is used for the RNA measurements. Over one thousand standard probes are already available and it only takes a few days to produce a customized probe for a new gene target.
Affymetrix' (Santa Clara, CA, USA) QuantiGene ViewRNA in situ hybridization (ISH) tissue assay will be automated on the Leica (Wetzlar, Germany) Bond RX staining platform. The partnership will significantly reduce assay time for single-copy RNA in situ hybridization (ISH) analysis. It will provide scientists with a powerful automated everyday solution for drug-discovery, translational research, and the development of new companion diagnostic tests for personalized medicine.
Consistent and rapid, the Leica Bond RX system automates the staining process. This means that investigators have access to same-day assay completion with a standardized staining protocol and rapid set-up for any probe.
George Bers, vice president and general manager of Expression Business Unit - Panomics at Affymetrix states, "We are excited by this partnership with Leica as it unlocks the true potential of single-copy RNA analysis and we believe it will accelerate the discovery of important new drugs and the validation of novel companion tests."
Affymetrix' QuantiGene ViewRNA ISH tissue assay will be available in the third quarter (Q3) of 2012. An optimized QuantiGene ViewRNA staining protocol will be preloaded onto the Leica BOND RX and a complete staining kit, including probes and all detection components, will be available from Affymetrix.
Related Links:
Affymetrix
Leica
 Rapid Test Kit.jpg)
The QuantiGene ViewRNA ISH tissue assay is used for the RNA measurements. Over one thousand standard probes are already available and it only takes a few days to produce a customized probe for a new gene target.
Affymetrix' (Santa Clara, CA, USA) QuantiGene ViewRNA in situ hybridization (ISH) tissue assay will be automated on the Leica (Wetzlar, Germany) Bond RX staining platform. The partnership will significantly reduce assay time for single-copy RNA in situ hybridization (ISH) analysis. It will provide scientists with a powerful automated everyday solution for drug-discovery, translational research, and the development of new companion diagnostic tests for personalized medicine.
Consistent and rapid, the Leica Bond RX system automates the staining process. This means that investigators have access to same-day assay completion with a standardized staining protocol and rapid set-up for any probe.
George Bers, vice president and general manager of Expression Business Unit - Panomics at Affymetrix states, "We are excited by this partnership with Leica as it unlocks the true potential of single-copy RNA analysis and we believe it will accelerate the discovery of important new drugs and the validation of novel companion tests."
Affymetrix' QuantiGene ViewRNA ISH tissue assay will be available in the third quarter (Q3) of 2012. An optimized QuantiGene ViewRNA staining protocol will be preloaded onto the Leica BOND RX and a complete staining kit, including probes and all detection components, will be available from Affymetrix.
Related Links:
Affymetrix
Leica
Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
New
HIV Test
Anti-HIV (1/2) Rapid Test Kit
New
Coagulation Analyzer
CS-2400
Latest Hematology News
- New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
- Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
- WBC Count Could Predict Severity of COVID-19 Symptoms
- New Platelet Counting Technology to Help Labs Prevent Diagnosis Errors
- Streamlined Approach to Testing for Heparin-Induced Thrombocytopenia Improves Diagnostic Accuracy
- POC Hemostasis System Could Help Prevent Maternal Deaths
- New Test Assesses Oxygen Delivering Ability of Red Blood Cells by Measuring Their Shape
- Personalized CBC Testing Could Help Diagnose Early-Stage Diseases in Healthy Individuals
- Non-Invasive Test Solution Determines Fetal RhD Status from Maternal Plasma
- First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC
- Next Gen CBC and Sepsis Diagnostic System Targets Faster, Earlier, Easier Results
- Newly Discovered Blood Group System to Help Identify and Treat Rare Patients
- Blood Platelet Score Detects Previously Unmeasured Risk of Heart Attack and Stroke
- Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere
- New Hematology Analyzers Deliver Combined ESR and CBC/DIFF Results in 60 Seconds
- Next Generation Instrument Screens for Hemoglobin Disorders in Newborns
Channels
Clinical Chemistry
view channel
‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection
Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more
Low-Cost Portable Screening Test to Transform Kidney Disease Detection
Millions of individuals suffer from kidney disease, which often remains undiagnosed until it has reached a critical stage. This silent epidemic not only diminishes the quality of life for those affected... Read more
New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma
Cancer diagnoses have traditionally relied on invasive or time-consuming procedures like tissue biopsies. Now, new research published in ACS Central Science introduces a method that utilizes pulsed infrared... Read more
Molecular Diagnostics
view channel
Cheap Cell-Free DNA Based Test Accurately Predicts Preterm Birth
Preterm birth (PTB) occurs in around 11% of all births globally, leading to considerable morbidity and mortality for both mothers and their newborns. Identifying pregnancies at risk of PTB early in gestation... Read more
RNA Blood Test Detects Cancers and Resistance to Treatment
A newly developed blood test offers the ability to detect cancer, understand how cancer resists treatments, and assess tissue damage from non-cancerous conditions. This innovative test, created by researchers... Read more
Immunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read more
Microbiology
view channel
Handheld Device Delivers Low-Cost TB Results in Less Than One Hour
Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Pathology
view channel
Rapid, Ultra-Sensitive, PCR-Free Detection Method Makes Genetic Analysis More Accessible
Genetic testing has been an important method for detecting infectious diseases, diagnosing early-stage cancer, ensuring food safety, and analyzing environmental DNA. For a long time, polymerase chain reaction... Read more
Spit Test More Accurate at Identifying Future Prostate Cancer Risk
Currently, blood tests that measure the level of a protein called prostate-specific antigen (PSA) are commonly used to identify men at higher risk for prostate cancer. This test is typically used based... Read more
DNA Nanotechnology Boosts Sensitivity of Test Strips
Since the Covid-19 pandemic, most people have become familiar with paper-based rapid test strips, also known as lateral flow immunoassays (LFIAs). These tests are used to quickly detect biomarkers that... Read more
Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures
Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read moreTechnology
view channel
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read more
Industry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more
